Aberrant Hetero-Disulfide Bond Formation by the Hypertriglyceridemia-Associated p.Gly185Cys APOA5 Variant (rs2075291)

Objective— Apolipoprotein A-V (apoA-V) is a low-abundance plasma protein that modulates triacylglycerol homeostasis. Gene transfer studies were undertaken in apoa5 (−/−) mice to define the mechanism underlying the correlation between the single-nucleotide polymorphism c.553G>T in APOA5 and hypertriglyceridemia. Approach and Results— Adeno-associated virus (AAV) 2/8–mediated gene transfer of wild-type apoA-V induced a dramatic lowering of plasma triacylglycerol in apoa5 (−/−) mice, whereas AAV2/8-Gly162Cys apoA-V (corresponding to the c.553G>T single-nucleotide polymorphism: rs2075291; p.Gly185Cys when numbering includes signal sequence) had a modest effect. Characterization studies revealed that plasma levels of wild-type and G162C apoA-V in transduced mice were similar and within the physiological range. Fractionation of plasma from mice transduced with AAV2/8-G162C apoA-V indicated that, unlike wild-type apoA-V, >50% of G162C apoA-V was recovered in the lipoprotein-free fraction. Nonreducing SDS-PAGE immunoblot analysis provided evidence that G162C apoA-V present in the lipoprotein-free fraction, but not that portion associated with lipoproteins, displayed altered electrophoretic mobility consistent with disulfide-linked heterodimer formation. Immunoprecipitation followed by liquid chromatography/mass spectrometry of human plasma from subjects homozygous for wild-type APOA5 and c.553G>T APOA5 revealed that G162C apoA-V forms adducts with extraneous plasma proteins including fibronectin, kininogen-1, and others. Conclusions— Substitution of Cys for Gly at position 162 of mature apoA-V introduces a free cysteine that forms disulfide bonds with plasma proteins such that its lipoprotein-binding and triacylglycerol-modulation functions are compromised.

[1]  J. Esko,et al.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. , 2013, The Journal of clinical investigation.

[2]  T. Forte,et al.  Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol , 2013, Current opinion in lipidology.

[3]  J. Simonsen,et al.  Gene Transfer of Apolipoprotein A-V Improves the Hypertriglyceridemic Phenotype of apoa5 (−/−) mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[4]  S. Young,et al.  Glycosylphosphatidylinositol‐anchored high‐density lipoprotein‐binding protein 1 and the intravascular processing of triglyceride‐rich lipoproteins , 2012, Journal of internal medicine.

[5]  D. Mikhailidis,et al.  Triglycerides: a case for treatment? , 2012, Current opinion in cardiology.

[6]  J. Kao,et al.  Functional importance of apolipoprotein A5 185G in the activation of lipoprotein lipase. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[7]  J. Aberle,et al.  Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia. , 2011, Atherosclerosis.

[8]  S. Young,et al.  Binding Preferences for GPIHBP1, a Glycosylphosphatidylinositol-Anchored Protein of Capillary Endothelial Cells , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[9]  V. Salomaa,et al.  Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia , 2010, Nature Genetics.

[10]  S. Vaessen,et al.  Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia. , 2009, Biochemical and biophysical research communications.

[11]  S. Young,et al.  The Acidic Domain of GPIHBP1 Is Important for the Binding of Lipoprotein Lipase and Chylomicrons* , 2008, Journal of Biological Chemistry.

[12]  N. Delsaux,et al.  Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[13]  T. Forte,et al.  Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice Published, JLR Papers in Press, December 3, 2007. , 2008, Journal of Lipid Research.

[14]  P. Kwok,et al.  patient-oriented and epidemiological research An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients , 2008 .

[15]  T. Forte,et al.  Apolipoprotein A-V association with intracellular lipid dropletss⃞ Published, JLR Papers in Press, April 25, 2007. , 2007, Journal of Lipid Research.

[16]  Le-ming Fan,et al.  A genetic variant c.553G > T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. , 2006, Atherosclerosis.

[17]  L. Pennacchio,et al.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. , 2005, The Journal of clinical investigation.

[18]  M. Nagano,et al.  A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration Published, JLR Papers in Press, June 16, 2005. DOI 10.1194/jlr.D500018-JLR200 , 2005, Journal of Lipid Research.

[19]  S. Nilsson,et al.  Apolipoprotein A-V-heparin Interactions , 2005, Journal of Biological Chemistry.

[20]  Yasushi Ishihama,et al.  Proteomic LC-MS systems using nanoscale liquid chromatography with tandem mass spectrometry. , 2005, Journal of chromatography. A.

[21]  A. Boodhoo,et al.  The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. , 2005, Clinical chemistry.

[22]  K. Chien,et al.  A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. , 2003, Human molecular genetics.

[23]  C. Kay,et al.  Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. , 2003, Biochemistry.

[24]  A. Shevchenko,et al.  Fast-response proteomics by accelerated in-gel digestion of proteins. , 2003, Analytical chemistry.

[25]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[26]  P. Reitsma,et al.  Apolipoprotein A-V A NOVEL APOLIPOPROTEIN ASSOCIATED WITH AN EARLY PHASE OF LIVER REGENERATION* , 2001 .

[27]  J. Hokanson,et al.  Hypertriglyceridemia as a cardiovascular risk factor. , 1998, The American journal of cardiology.

[28]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[29]  K. Weisgraber Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. , 1990, Journal of lipid research.

[30]  M. Jauhiainen,et al.  Interaction of lipoprotein(a) with fibronectin and its potential role in atherogenesis. , 1990, European heart journal.